Heart Attack

Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...

BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...

DEL MAR, Calif., June 24, 2026 CeleCor Therapeutics announced the completion of its New Drug Application (NDA) submission to...